Quest Diagnostics (NYSE:DGX) Shares Unloaded Rep. Julie Johnson

Posted by Mitch Edgeman on Dec 19th, 2025

Representative Julie Johnson (D-Texas) recently sold shares of Quest Diagnostics Incorporated (NYSE:DGX). In a filing disclosed on December 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Quest Diagnostics stock on November 3rd. The trade occurred in the Representative’s “MERRILL LYNCH LONG TERM GROWTH” account.

Representative Julie Johnson also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 11/13/2025.
Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Cigna Group (NYSE:CI) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Xcel Energy (NASDAQ:XEL) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/13/2025.
Sold $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 11/13/2025.

Quest Diagnostics Stock Down 0.4%

Shares of DGX stock traded down $0.78 on Friday, reaching $175.37. 245,664 shares of the stock were exchanged, compared to its average volume of 1,104,313. The company has a current ratio of 1.13, a quick ratio of 1.04 and a debt-to-equity ratio of 0.71. Quest Diagnostics Incorporated has a twelve month low of $148.70 and a twelve month high of $197.55. The company has a market capitalization of $19.51 billion, a price-to-earnings ratio of 20.59, a PEG ratio of 2.41 and a beta of 0.62. The business’s 50 day moving average price is $183.51 and its 200 day moving average price is $179.80.

Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its quarterly earnings data on Tuesday, October 21st. The medical research company reported $2.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.51 by $0.09. Quest Diagnostics had a return on equity of 15.47% and a net margin of 8.91%.The company had revenue of $2.82 billion for the quarter, compared to analyst estimates of $2.73 billion. During the same quarter last year, the company posted $2.30 earnings per share. The business’s quarterly revenue was up 13.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. As a group, sell-side analysts expect that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 13th will be issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 1.8%. The ex-dividend date is Tuesday, January 13th. Quest Diagnostics’s payout ratio is 37.56%.

Insider Buying and Selling

In other Quest Diagnostics news, Director Vicky B. Gregg sold 1,250 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $191.76, for a total value of $239,700.00. Following the transaction, the director owned 17,037 shares of the company’s stock, valued at approximately $3,267,015.12. The trade was a 6.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO J. E. Davis sold 55,093 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $192.22, for a total transaction of $10,589,976.46. Following the completion of the sale, the chief executive officer directly owned 120,480 shares of the company’s stock, valued at approximately $23,158,665.60. This represents a 31.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 94,461 shares of company stock valued at $17,957,361 in the last ninety days. 8.16% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Quest Diagnostics

A number of institutional investors have recently bought and sold shares of the stock. G&S Capital LLC acquired a new position in Quest Diagnostics during the 2nd quarter worth $1,262,000. Fred Alger Management LLC raised its stake in shares of Quest Diagnostics by 9.9% in the first quarter. Fred Alger Management LLC now owns 19,378 shares of the medical research company’s stock valued at $3,279,000 after purchasing an additional 1,745 shares in the last quarter. Martin Capital Partners LLC lifted its holdings in shares of Quest Diagnostics by 194.2% during the 2nd quarter. Martin Capital Partners LLC now owns 5,107 shares of the medical research company’s stock worth $917,000 after acquiring an additional 3,371 shares during the period. Game Plan Financial Advisors LLC acquired a new stake in Quest Diagnostics during the first quarter valued at approximately $1,611,000. Finally, First American Bank bought a new stake in Quest Diagnostics in the second quarter valued at $568,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on DGX shares. Weiss Ratings reiterated a “buy (b)” rating on shares of Quest Diagnostics in a research note on Wednesday, October 8th. Barclays upped their price objective on shares of Quest Diagnostics from $190.00 to $195.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 22nd. Mizuho boosted their price target on Quest Diagnostics from $190.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, October 17th. Jefferies Financial Group increased their price objective on shares of Quest Diagnostics from $200.00 to $215.00 and gave the stock a “buy” rating in a research report on Tuesday, October 21st. Finally, Evercore ISI raised their target price on Quest Diagnostics from $185.00 to $190.00 and gave the company an “in-line” rating in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $197.27.

View Our Latest Report on DGX

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Quest Diagnostics

(Get Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.